Literature DB >> 15547952

Semi-parametric and non-parametric methods for clinical trials with incomplete data.

Peter C O'Brien1, David Zhang, Kent R Bailey.   

Abstract

Last observation carried forward (LOCF) and analysis using only data from subjects who complete a trial (Completers) are commonly used techniques for analysing data in clinical trials with incomplete data when the endpoint is change from baseline at last scheduled visit. We propose two alternative methods. The semi-parametric method, which cumulates changes observed between consecutive time points, is conceptually similar to the familiar life-table method and corresponding Kaplan-Meier estimation when the primary endpoint is time to event. A non-parametric analogue of LOCF is obtained by carrying forward, not the observed value, but the rank of the change from baseline at the last observation for each subject. We refer to this method as the LRCF method. Both procedures retain the simplicity of LOCF and Completers analyses and, like these methods, do not require data imputation or modelling assumptions. In the absence of any incomplete data they reduce to the usual two-sample tests. In simulations intended to reflect chronic diseases that one might encounter in practice, LOCF was observed to produce markedly biased estimates and markedly inflated type I error rates when censoring was unequal in the two treatment arms. These problems did not arise with the Completers, Cumulative Change, or LRCF methods. Cumulative Change and LRCF were more powerful than Completers, and the Cumulative Change test provided more efficient estimates than the Completers analysis, in all simulations. We conclude that the Cumulative Change and LRCF methods are preferable to LOCF and Completers analyses. Mixed model repeated measures (MMRM) performed similarly to Cumulative Change and LRCF and makes somewhat less restrictive assumptions about missingness mechanisms, so that it is also a reasonable alternative to LOCF and Completers analyses. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15547952     DOI: 10.1002/sim.1963

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial.

Authors:  W Poon; C Matula; P E Vos; D F Muresanu; N von Steinbüchel; K von Wild; V Hömberg; E Wang; T M C Lee; S Strilciuc; J C Vester
Journal:  Neurol Sci       Date:  2019-09-07       Impact factor: 3.307

2.  Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.

Authors:  M K Park; H Babaali; L I Gilbert-McClain; M Stylianou; J Joo; J Moss; V C Manganiello
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2009-07       Impact factor: 0.670

3.  Secondary prevention of hazardous alcohol consumption in psychiatric out-patients: a randomised controlled study.

Authors:  Sophia Eberhard; Göran Nordström; Peter Höglund; Agneta Ojehagen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-03-18       Impact factor: 4.328

4.  Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.

Authors:  Farrukh T Awan; Neil E Kay; Melanie E Davis; Wenting Wu; Susan M Geyer; Nelson Leung; Diane F Jelinek; Renee C Tschumper; Charla R Secreto; Thomas S Lin; Michael R Grever; Tait D Shanafelt; Clive S Zent; Timothy G Call; Nyla A Heerema; Gerard Lozanski; John C Byrd; David M Lucas
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

5.  Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.

Authors:  Johannes C Vester; Anca D Buzoianu; Stefan I Florian; Volker Hömberg; Se-Hyuk Kim; Tatia M C Lee; Christian Matula; Wai Sang Poon; Dorel Sandesc; Nicole von Steinbüchel; Stefan Strilciuc; Pieter E Vos; Klaus von Wild; Dafin Muresanu
Journal:  Neurol Sci       Date:  2021-02-23       Impact factor: 3.307

6.  The clinical significance of CDK1 expression in oral squamous cell carcinoma.

Authors:  Xin Chen; Feng-He Zhang; Qiao-Er Chen; Yuan-Yin Wang; Yin-Long Wang; Jia-Cai He; Jian Zhou
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-01-01

7.  Comparison of the Impact of Zika and Dengue Virus Infection, and Other Acute Illnesses of Unidentified Origin on Cognitive Functions in a Prospective Cohort in Chiapas Mexico.

Authors:  Pablo F Belaunzarán-Zamudio; Ana M Ortega-Villa; Alberto J Mimenza-Alvarado; Paola Del Carmen Guerra-De-Blas; Sara G Aguilar-Navarro; Jesús Sepúlveda-Delgado; Sally Hunsberger; Raydel Valdés Salgado; José Ramos-Castañeda; Héctor Armando Rincón León; Paul Rodríguez de La Rosa; José Gabriel Nájera Cancino; John Beigel; Sandra Caballero Sosa; Emilia Ruiz Hernández; John H Powers; Guillermo M Ruiz-Palacios; Clifford Lane
Journal:  Front Neurol       Date:  2021-03-22       Impact factor: 4.003

8.  Cocreated internet-based stepped care for individuals with cancer and concurrent symptoms of anxiety and depression: Results from the U-CARE AdultCan randomized controlled trial.

Authors:  Anna Hauffman; Sven Alfonsson; Anna Bill-Axelson; Leif Bergkvist; Marina Forslund; Susanne Mattsson; Louise von Essen; Peter Nygren; Helena Igelström; Birgitta Johansson
Journal:  Psychooncology       Date:  2020-09-22       Impact factor: 3.894

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.